Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 26Melanoma 18Neoplasm Metastasis 14Neoplasms 12Squamous Cell Carcinoma of Head and Neck 10Recurrence 9Ovarian Neoplasms 7Skin Neoplasms 6Head and Neck Neoplasms 5Carcinoma, Squamous Cell 5Carcinoma, Renal Cell 5Carcinoma, Basal Cell 5Triple Negative Breast Neoplasms 4Fallopian Tube Neoplasms 4Breast Neoplasms 4Uterine Cervical Neoplasms 3Urinary Bladder Neoplasms 3Stomach Neoplasms 3Prostatic Neoplasms 3Multiple Myeloma 3Endometrial Neoplasms 3Colorectal Neoplasms 3Colonic Neoplasms 3Carcinoma, Merkel Cell 3Adenocarcinoma 3Sarcoma 2Pancreatic Neoplasms 2Lymphoma 2Lung Neoplasms 2Glioma 2

Interventions

pembrolizumab 3Ramucirumab 2Nivolumab 2etirinotecan pegol 1cemiplimab 1Paclitaxel 1Injections 1Fluorouracil 1Docetaxel 1Decitabine 1Cisplatin 1Carboplatin 1Antibodies, Bispecific 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Malignant Solid Tumor × cemiplimab × Clear all
NCT03192345 2024-08-07

A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and Cemiplimab in Patients With Advanced Solid Tumors

Sanofi

Phase 1 Completed
161 enrolled
Other solid neoplasm

Malignant Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡